
November 6, 2026
Permanent Medicare Drug Price Negotiations A new Centers for Medicare and Medicaid Services’ (CMS) regulation will set a permanent process and framework for Medicare drug price negotiations under the Inflation Reduction Act (IRA). This will ensure the program continues beyond 2029. The rule codifies and expands policies previously established through guidance for the initial 2026-28 period. For the 2029 round, by Feb. 1 CMS will select up to 20 drugs covered under Medicare Part B or Part D for price negotiations, with the potential to also select medicines included in previous rounds for renegotiation. I have championed the Trump administration’s efforts on drug prices across the board. This is yet another signal that Trump is serious. You would not have guessed that a Biden-era reform would have been so thoroughly endorsed. #drugpricing #trump #medicare https://www.fiercepharma.com/pharma/cms-makes-it-official-codifying-medicare-drug-price-negotiations-rolled-out-under-ira Humana Q3 Financials Humana beat The Street for both earnings and revenue in Q3



